Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus AREDIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus AREDIA.
ACTONEL vs AREDIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
90 mg intravenously over 2 hours every 3-4 weeks for hypercalcemia of malignancy; 90 mg intravenously over 2 hours every 4 weeks for osteolytic bone metastases of breast cancer or multiple myeloma.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Multiphasic; terminal half-life is approximately 300 hours (range 200-400 hours) reflecting slow release from bone. Clinically, this results in prolonged suppression of bone resorption lasting weeks after a single dose.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Primarily eliminated unchanged via renal excretion (about 30-40% of administered dose within 24 hours); remainder sequestered in bone and slowly released over months. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Bisphosphonate
Bisphosphonate